drugset / Trial / NCT00803842

Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash

NCT00803842

Non-randomizedSingle-groupOpen-labelSupportive care

Summary

A side effect occurring in a majority of patients taking erlotinib (Tarceva®) consists of a skin rash. Sometimes, symptoms associated with the rash necessitate erlotinib dose reduction or discontinuation. Some physicians have successfully treated the erlotinib-induced rash with doxycycline. At the same time, it has been observed that in patients who develop the erlotinib rash, the cancers respond better to erlotinib treatment. This research study is designed to determine how well doxycycline treats the erlotinib rash and whether doxycycline affects the blood levels of erlotinib.

Timeline

Start
2008-10
Primary completion
2009-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Doxycycline Small molecule 100 mg Oral